A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

Summary

This is a Phase 1b/2, open-label, 2-part, global study designed to investigate the anti-tumor activity as well as the safety and efficacy of BAT8006 in subjects with platinum resistance ovarian cancer

Timeline

Start

2025-01-31

Primary completion

2026-03-10

Completion

2028-01-31

Outcome

Outcome not reported

Stopped: “Reconsideration of the subsequent international development of BAT8006”

Drugs

Indications